Last quarter (Q4 2022), bioMerieux's total revenue was €―, a decrease of ― from the same quarter last year. In Q4, bioMerieux's net income was €―. See bioMerieux’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	€ 3.59B	€ 3.38B	€ 3.12B	€ 2.63B	€ 2.42B
Cost of Revenue	-	€ 1.58B	€ 1.41B	€ 1.36B	€ 1.21B	€ 1.12B
Gross Profit	-	€ 2.01B	€ 1.96B	€ 1.75B	€ 1.43B	€ 1.30B
Operating Expense	-	€ 1.34B	€ 1.16B	€ 1.16B	€ 1.08B	€ 956.30M
Operating Income	-	€ 663.70M	€ 801.00M	€ 612.40M	€ 329.00M	€ 346.10M
Net Non Operating Interest Income Expense	-	€ -5.20M	€ -6.10M	€ -28.60M	€ -23.10M	€ -17.50M
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	€ 580.50M	€ 774.30M	€ 524.40M	€ 347.40M	€ 320.80M
Tax Provision	-	€ 140.10M	€ 175.60M	€ 121.50M	€ 77.80M	€ 65.10M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	€ 452.40M	€ 601.10M	€ 404.40M	€ 272.80M	€ 256.50M
Basic EPS	-	-	€ 5.08	€ 3.42	€ 2.31	€ 2.18
Diluted EPS	-	-	€ 5.06	€ 3.41	€ 2.30	€ 2.17
Basic Average Shares	-	-	€ 118.27M	€ 118.15M	€ 118.30M	€ 117.79M
Diluted Average Shares	-	-	€ 118.89M	€ 118.65M	€ 118.71M	€ 118.41M
Dividend Per Share	-	-	€ 0.62	€ 0.00	€ 0.35	€ 0.34
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	€ 2.93B	€ 2.58B	€ 2.52B	€ 2.29B	€ 2.08B
Net Income From Continuing And Discontinued Operation	-	€ 452.40M	€ 601.10M	€ 404.40M	€ 272.80M	€ 256.50M
Normalized Income	-	€ 513.88M	€ 616.17M	€ 454.57M	€ 286.69M	€ 263.75M
Interest Expense	-	€ 4.10M	€ 9.10M	€ 25.10M	€ 20.60M	€ 19.70M
EBIT	-	€ 584.60M	€ 783.40M	€ 549.40M	€ 368.00M	€ 340.50M
EBITDA	-	€ 861.60M	€ 1.01B	€ 760.20M	€ 557.50M	€ 517.50M

Currency in EUR

bioMerieux Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing